Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation monthly Stock Chart
Celgene Corporation
IndexS&P 500 P/E49.18 EPS (ttm)2.49 Insider Own0.20% Shs Outstand776.90M Perf Week-1.76%
Market Cap94.98B Forward P/E13.92 EPS next Y8.78 Insider Trans41.58% Shs Float775.89M Perf Month-0.90%
Income2.00B PEG2.18 EPS next Q1.63 Inst Own80.20% Short Float1.15% Perf Quarter8.52%
Sales11.23B P/S8.46 EPS this Y28.10% Inst Trans0.34% Short Ratio2.42 Perf Half Y22.24%
Book/sh8.49 P/B14.40 EPS next Y21.59% ROA7.40% Target Price140.04 Perf Year11.23%
Cash/sh10.26 P/C11.92 EPS next 5Y22.61% ROE35.00% 52W Range94.42 - 127.64 Perf YTD5.62%
Dividend- P/FCF25.40 EPS past 5Y11.80% ROI11.70% 52W High-3.39% Beta1.77
Dividend %- Quick Ratio3.50 Sales past 5Y18.30% Gross Margin96.10% 52W Low30.60% ATR1.80
Employees7132 Current Ratio3.70 Sales Q/Q16.30% Oper. Margin25.00% RSI (14)48.83 Volatility1.34% 1.37%
OptionableYes Debt/Eq2.17 EPS Q/Q-22.20% Profit Margin17.80% Rel Volume0.94 Prev Close122.26
ShortableYes LT Debt/Eq2.09 EarningsApr 27 BMO Payout0.00% Avg Volume3.69M Price123.31
Recom1.80 SMA20-0.78% SMA500.32% SMA2008.18% Volume787,523 Change0.86%
Mar-09-17Initiated UBS Buy $140
Nov-09-16Downgrade Standpoint Research Buy → Hold
Nov-08-16Initiated Mizuho Buy $130
Jul-15-16Initiated Stifel Buy $138
Apr-29-16Reiterated Sun Trust Rbsn Humphrey Buy $145 → $147
Feb-25-16Initiated Citigroup Buy $130
Jan-20-16Initiated Credit Suisse Outperform
Jan-14-16Initiated Standpoint Research Buy $130
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $145
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Nov-06-15Reiterated UBS Buy $156 → $145
Oct-01-15Upgrade JP Morgan Neutral → Overweight
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $160
Jul-24-15Reiterated UBS Buy $142 → $156
Jul-24-15Reiterated JMP Securities Mkt Outperform $133 → $147
Jul-24-15Reiterated Cantor Fitzgerald Buy $146 → $163
Jul-21-15Reiterated Piper Jaffray Overweight $144 → $160
Jul-15-15Reiterated RBC Capital Mkts Outperform $135 → $150
Jul-15-15Reiterated Barclays Equal Weight $120 → $130
Apr-24-17 08:21AM  9 Reasons Celgene Could Be the World's Most Perfect Stock Motley Fool
Apr-23-17 06:55PM  Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
11:01AM  3 Stocks That Growth Investors Should Love Motley Fool
Apr-22-17 07:26AM  3 Top Stocks to Buy With Your Tax Refund Motley Fool
Apr-21-17 04:13PM  Street Watches To See If $125,000 Drug Boosts Biogen's Results Investor's Business Daily
12:05PM  Celgene research leader Dr. Rupert Vessey joins Juno board American City Business Journals
08:48AM  Celgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : April 21, 2017 Capital Cube
Apr-20-17 05:53PM  What to expect from biotech CNBC Videos
02:55PM  Celgene to expand in Cambridge, taking former Amgen space American City Business Journals
Apr-19-17 08:04AM  Looking for a Smart Way to Use Your Tax Refund? Buy These 3 Stocks Motley Fool
Apr-18-17 04:01PM  Dow's Johnson & Johnson Highlights 'Multiple Issues' For Drugs, Biotechs Investor's Business Daily
Apr-17-17 08:42AM  3 Cancer Drug Stocks That Could Make You Rich Motley Fool
Apr-14-17 02:43PM  Celgene Stock History: The Biotech's Path to Gigantic Gains Motley Fool
Apr-13-17 04:18PM  The Hot Stock: Alexion Pharmaceuticals Climbs 3.3%
09:43AM  3 Rock-Solid Stocks to Buy Before the Next Market Crash Motley Fool
Apr-12-17 09:10AM  Short Sellers Back Off Major Biotechs 24/7 Wall St.
06:28AM  Biotechs Catching Their Breath: Cramer's 'Off The Charts'
06:00AM  First Quarter Earnings Preview: Biotech Heavyweights Investopedia
Apr-11-17 06:53PM  Cramer's charts show these biotechs ignoring their 'polit... CNBC Videos
06:22PM  Cramer's charts show these biotechs ignoring their 'political red herring' CNBC
06:05PM  OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal Zacks
12:49PM  3 Stocks for the Long Haul Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Amazon, Celgene, Facebook and Walgreens Boots Zacks
Apr-10-17 05:46PM  Top Research Reports for Today: AMZN, CELG, FB, WBA Zacks
05:10PM  Peninsula biotech tumbles as cancer trial fails, Bayer nixes drug option American City Business Journals
08:23AM  OncoMed's pancreatic cancer drug fails mid-stage study Reuters
Apr-08-17 04:11PM  3 Big Biotech Stocks With Big-Time Catalysts Motley Fool
09:35AM  Big Tech and Biotech Trades Highlight Insider Selling: Gap, Adobe, Celgene, Splunk and More 24/7 Wall St.
12:01AM  [$$] Celgene Outlook Brightens, While Gilead Faces Woes
Apr-07-17 04:07PM  ETFs with exposure to Celgene Corp. : April 7, 2017 Capital Cube
02:43PM  Would Gilead Sciences Make This Staggeringly Audacious Move? Motley Fool
02:00PM  Earnings Preview: Biotechnology Looks Healthy
01:34PM  Why Roche's New Drug Is Bad News For Biogen
09:41AM  3 Perfect Stocks You Can Buy Now Motley Fool
07:30AM  Today's Research Reports on Top Biotech Stocks: Gilead Sciences and Celgene Accesswire
Apr-06-17 04:37PM  Dow Up, Cat Leads, Celgene Firm; Will These 5 Stocks Dispel Trump Trade-War Fears? Investor's Business Daily
Apr-05-17 03:36PM  Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst Zacks
08:59AM  Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug Zacks
08:15AM  Blog Coverage Aviragen to Explore Strategic Alternatives; Cuts Headcount by 25% Accesswire
Apr-03-17 06:00PM  Celgene Notified of ANDA Filing for POMALYST® Business Wire
08:01AM  5 Best Growth Stocks to Own as Core Holdings in Your Portfolio Motley Fool
07:30AM  Celgene Corporation to Announce First Quarter 2017 Results on April 27, 2017 Business Wire
Apr-02-17 07:41AM  3 Big Healthcare Stocks That Wall Street Predicts Will Grow the Fastest Motley Fool
Apr-01-17 11:42AM  Better Buy: Celgene Corporation vs. Amgen Inc. Motley Fool
Mar-31-17 12:21PM  Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?
12:00PM  My 3 Top Biotech Stocks to Buy Now Motley Fool
09:43AM  Can Vertex Keep Climbing? at
07:27AM  3 Stocks We Can't Wait to Buy on Sale at Motley Fool
Mar-30-17 11:48AM  Here's Why Halozyme Therapeutics, Inc Is Falling at Motley Fool
11:03AM  No. 5-Ranked Biotech Bolts Higher On Drug Results
Mar-29-17 04:21PM  Top Biotech Stocks for Growth Investors at Motley Fool
08:32AM  These Charts Suggest Biotech Is Heading Higher at Investopedia
Mar-28-17 09:12AM  Will These Three Drugs Continue Driving Celgene's Top-Line Growth?
07:23AM  3 Least Risky Biotech Stocks on the Market at Motley Fool
Mar-27-17 04:29PM  3 Top Cancer Drug Stocks to Buy in 2017 at Motley Fool
03:51PM  ETFs with exposure to Celgene Corp. : March 27, 2017
03:22PM  Nasdaq Turns Positive; 3 Medicals To Watch; Will Snap Complete A Base?
10:30AM  Short Interest Pulls Back in Major Biotechs
09:46AM  Better Buy: Celgene Corporation vs. Gilead Sciences at Motley Fool
06:00AM  5 Stocks to Invest Your Tax Refund In at Motley Fool
Mar-26-17 11:01AM  3 Great Stocks to Buy in a Market Pullback at Motley Fool
09:27AM  3 of the Safest Stocks You Can Buy Right Now at Motley Fool
Mar-24-17 01:13PM  2 Asset Classes That Are Arguably Still Cheap at Motley Fool
Mar-22-17 09:30AM  Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
07:37AM  A Look at Ionis Pharmaceuticals Spinraza
Mar-21-17 05:52PM  3 Value Stocks Senior Citizens Could Buy Right Now at Motley Fool
Mar-20-17 10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
09:50AM  Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now
09:17AM  Leerink Presents: Your 2017 Biopharma Catalyst Tracker
08:42AM  4 Stocks at 52-Week Highs That Are Still Worth Buying Today at Motley Fool
Mar-17-17 08:43AM  Celgene Corp. :CELG-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
Mar-16-17 07:08AM  [$$] Celgene Shows Savvy as Gilead Keeps Backsliding at
Mar-15-17 04:43PM  5 Things You Probably Didn't Know About Celgene Corporation at Motley Fool
04:29PM  Top Biotech Hits Buy Point As CEO Cites 'Momentum' In Key Drivers
Mar-14-17 11:08AM  Credit Suisse's Top 10 Stocks for 2017
10:35AM  Amgen's Repatha Meets Primary Endpoint in Phase III Study
Mar-12-17 02:57PM  Top Biotech May 'Unveil' Breakthrough Treatment And Breakout Move
Mar-10-17 04:41PM  Top Stocks Billionaires Are Buying Now at Motley Fool
04:39PM  Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging'
11:30AM  Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus
10:30AM  Major Biotechs See a Retreat in Short Interest
09:03AM  The 3 Drugs Powering Celgene to the Top of Your Portfolio at Motley Fool
Mar-09-17 06:32PM  Top Research Reports for March 9, 2017
04:03PM  Will Pfizer Take On Celgene, Other Rivals With Leukemia Drug?
01:57PM  Celgene's Deep Pipeline Can Reassure Investors
01:40PM  Drugs, travel, jewelry and social media in the blitz
10:00AM  Coverage initiated on Celgene by UBS
09:03AM  5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade at Motley Fool
Mar-08-17 05:17PM  Valeant (VRX) Issues Notes, Restructures Debt; Shares Down
04:55PM  Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug
09:45AM  Ionis Pharma Lipid Disorder Candidate Positive in Phase III
09:32AM  3 Safe Stocks You Can Buy Right Now at Motley Fool
08:18AM  Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal
Mar-07-17 04:08PM  GlaxoSmithKline's Nucala Positive in Label Expansion Study
03:58PM  Biotech beat up?
03:04PM  3 Biotech Stocks You Don't Have to Babysit at Motley Fool
09:48AM  Trump's Latest Drug Pricing Tweet Hits Biotech Stocks at The Wall Street Journal
08:04AM  Here's Why the Best Is Yet to Come for Gilead Sciences, Inc. at Motley Fool
Mar-06-17 10:20AM  Red-Hot Biotech Companies Highlight Jefferies Top Stocks to Buy
08:41AM  J&J Presents Positive Phase III Data on Psoriasis Candidate
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc.; The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM
HUGIN ROBERT Jsee remarksJan 05Option Exercise27.4322,708622,767913,909Jan 09 04:11 PM
Smith Scott AndrewSee RemarksDec 23Option Exercise0.006,400039,875Dec 27 04:17 PM
PEHL MICHAEL F.See remarksDec 02Option Exercise0.001,88001,880Dec 06 04:05 PM
Smith Scott AndrewSee RemarksDec 02Option Exercise0.003,750035,419Dec 06 04:05 PM
FOUSE JACQUALYN Asee remarksDec 02Option Exercise0.005,000084,392Dec 06 04:04 PM
Alles Mark JSee RemarksDec 02Option Exercise0.006,5600166,134Dec 06 04:03 PM
VESSEY RUPERTSee remarksNov 22Sale123.182,500307,9501,150Nov 30 04:15 PM
PEHL MICHAEL F.See remarksNov 10Option Exercise68.3920,4241,396,77022,052Nov 15 04:22 PM
PEHL MICHAEL F.See remarksNov 10Sale121.0422,0522,669,1490Nov 15 04:22 PM
Friedman Michael ADirectorNov 09Option Exercise31.8018,600591,48018,600Nov 10 04:14 PM
Friedman Michael ADirectorNov 09Sale116.1018,6002,159,4600Nov 10 04:14 PM
HUGIN ROBERT Jsee remarksNov 09Sale120.00100,00012,000,000922,201Nov 14 05:47 PM
CELGENE CORP /DE/10% OwnerOct 24Buy14.00800,15011,202,1004,834,980Oct 26 04:15 PM
CASEY MICHAEL DDirectorOct 18Option Exercise100.067,500750,45092,985Oct 19 04:16 PM
Friedman Michael ADirectorOct 03Option Exercise29.8656,1161,675,36456,116Oct 05 04:09 PM
Friedman Michael ADirectorOct 03Sale103.6656,1165,816,9850Oct 05 04:09 PM
BARKER RICHARD WDirectorSep 23Option Exercise36.9220,000738,40031,332Sep 26 04:08 PM
BARKER RICHARD WDirectorSep 23Sale110.8220,0002,216,40011,332Sep 26 04:08 PM
MARIO ERNESTDirectorSep 23Sale109.4215,0001,641,30090,058Sep 26 04:08 PM
KAPLAN GILLADirectorSep 19Option Exercise29.267,500219,45079,642Sep 20 04:42 PM
KAPLAN GILLADirectorSep 15Sale106.449,7101,033,53272,142Sep 16 04:15 PM
LOUGHLIN JAMES JDirectorAug 23Option Exercise26.3627,500724,85050,419Aug 24 04:28 PM
LOUGHLIN JAMES JDirectorAug 23Sale114.1027,5003,137,75022,919Aug 24 04:28 PM
CASEY MICHAEL DDirectorAug 22Sale114.0143,1344,917,70785,485Aug 23 04:29 PM
HUGIN ROBERT Jsee remarksJul 28Sale110.00100,00011,000,0001,022,201Aug 01 05:04 PM
MARIO ERNESTDirectorJul 01Option Exercise0.007330105,058Jul 05 04:32 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00733022,919Jul 05 04:30 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073300Jul 05 04:27 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00733081,852Jul 05 04:28 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00733023,146Jul 05 04:27 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00733011,551Jul 05 04:25 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073300Jul 05 04:26 PM
HUGIN ROBERT Jsee remarksJun 20Sale100.1675,0007,512,0001,122,201Jun 22 04:42 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333081,119Jun 17 04:18 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 17 04:13 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 17 04:14 PM
MARIO ERNESTDirectorJun 16Option Exercise0.002,0550113,892Jun 16 06:57 PM
COX CARRIE SMITHDirectorJun 16Option Exercise0.006,200022,413Jun 17 04:14 PM
KAPLAN GILLADirectorJun 15Option Exercise0.006,200080,786Jun 17 04:18 PM
LOUGHLIN JAMES JDirectorJun 12Option Exercise0.002,068021,853Jun 13 05:10 PM
MARIO ERNESTDirectorJun 12Option Exercise0.002,0680103,992Jun 13 05:10 PM
KAPLAN GILLADirectorJun 12Option Exercise0.002,068074,586Jun 13 05:09 PM
BARKER RICHARD WDirectorJun 12Option Exercise0.002,068011,439Jun 13 05:08 PM
CASEY MICHAEL DDirectorJun 12Option Exercise0.002,06800Jun 13 05:08 PM
Friedman Michael ADirectorJun 12Option Exercise0.002,06800Jun 13 05:09 PM
Alles Mark JSee RemarksApr 29Option Exercise0.0011,0000164,636May 03 04:30 PM
HUGIN ROBERT Jsee remarksApr 29Option Exercise0.0060,00001,228,311May 03 04:19 PM
Smith Scott AndrewSee RemarksApr 29Option Exercise0.0010,000036,656May 03 09:28 PM
MARIO ERNESTDirectorApr 26Option Exercise31.805,000158,975101,924Apr 28 04:09 PM